Melissa Yuwono Tjota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melissa Yuwono Tjota has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Tatjana Antic
Department of Pathology, University of Chicago, Chicago, USA
8 shared publications Jeremy Segal
6 shared publications- Kelly L. Close
Close Concerns, San Francisco, California
6 shared publications Eric M. Chang
5 shared publications- Anne I. Sperling
Department of Medicine, University of Virginia, Charlottesville, VA, USA
4 shared publications - Jesse W. Williams
Center for Immunology, University of Minnesota, Minneapolis, MN, USA
4 shared publications
Latest Publications
- 25 September 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
Clonal Relatedness Index
- 25 September 2026
- Published by Elsevier in The Journal of Molecular Diagnostics
Clonal Relatedness Index
- Open Access
- 13 August 2026
- Published by Wiley in Histopathology
- Vol. 89 (6) , 1083-1094
Clinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB ‐amplified renal cell carcinoma: a comprehensive study of 15 cases
Aims: Eosinophilic solid and cystic renal cell carcinoma (ESC‐RCC) and TFEB ‐amplified renal cell carcinoma ( TFEB ‐amplified RCC, a subset of TFEB‐ altered RCC) are rare eosinophilic renal cell tumours that can be difficult to distinguish on the basis of morphology and immunohistochemistry alone. In this study, we compared the clinicopathological and molecular features of these entities to identify distinguishing characteristics. Methods and results: Nine cases of ESC‐RCC and six cases of TFEB ‐amplified RCC from our institutional archives were evaluated for clinical, morphological, immunohistochemical and molecular features. Despite morphological overlap, each entity exhibited somewhat distinctive features. ESC‐RCC frequently exhibited solid and cystic architecture with tightly packed tubules, flocculent to coarsely granular cytoplasm with basophilic stippling and prominent admixed macrophages. In comparison, TFEB ‐amplified RCC more frequently demonstrated solid growth of pseudopapillae and loose tubules, dense eosinophilic granular cytoplasm without basophilic stippling, focally apical nuclei and extracellular magenta globules. However, neither morphology nor immunohistochemistry was sufficiently specific to completely distinguish these entities. Ancillary molecular testing identified pathogenic TSC1 or TSC2 gene variants in ESC‐RCC and TFEB gene locus amplification in TFEB ‐amplified RCC. Conclusions: Although ESC‐RCC and TFEB ‐RCC share overlapping morphological and immunohistochemical features, each demonstrates somewhat characteristic histological findings. Definitive distinction requires molecular testing to identify the underlying molecular alterations. As molecular testing assumes an increasingly important role in RCC diagnosis and classification, recognition of these rare entities and their overlapping and distinguishing features is essential for appropriate testing and accurate diagnosis.
- 13 August 2026
- Published by Wiley in Histopathology
- Vol. 89 (6) , 1083-1094
Open AccessClinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB ‐amplified renal cell carcinoma: a comprehensive study of 15 cases
Aims: Eosinophilic solid and cystic renal cell carcinoma (ESC‐RCC) and TFEB ‐amplified renal cell carcinoma ( TFEB ‐amplified RCC, a subset of TFEB‐ altered RCC) are rare eosinophilic renal cell tumours that can be difficult to distinguish on the basis of morphology and immunohistochemistry alone. In this study, we compared the clinicopathological and molecular features of these entities to identify distinguishing characteristics. Methods and results: Nine cases of ESC‐RCC and six cases of TFEB ‐amplified RCC from our institutional archives were evaluated for clinical, morphological, immunohistochemical and molecular features. Despite morphological overlap, each entity exhibited somewhat distinctive features. ESC‐RCC frequently exhibited solid and cystic architecture with tightly packed tubules, flocculent to coarsely granular cytoplasm with basophilic stippling and prominent admixed macrophages. In comparison, TFEB ‐amplified RCC more frequently demonstrated solid growth of pseudopapillae and loose tubules, dense eosinophilic granular cytoplasm without basophilic stippling, focally apical nuclei and extracellular magenta globules. However, neither morphology nor immunohistochemistry was sufficiently specific to completely distinguish these entities. Ancillary molecular testing identified pathogenic TSC1 or TSC2 gene variants in ESC‐RCC and TFEB gene locus amplification in TFEB ‐amplified RCC. Conclusions: Although ESC‐RCC and TFEB ‐RCC share overlapping morphological and immunohistochemical features, each demonstrates somewhat characteristic histological findings. Definitive distinction requires molecular testing to identify the underlying molecular alterations. As molecular testing assumes an increasingly important role in RCC diagnosis and classification, recognition of these rare entities and their overlapping and distinguishing features is essential for appropriate testing and accurate diagnosis.
- Open Access
- 6 June 2026
- Published by Wiley in Histopathology
NFE2L2 ‐mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD ‐ L1 expression
Aims: NFE2L2 encodes the transcription factor, NRF2, which is a regulator of cellular oxidative stress responses and metabolic homeostasis. NFE2L2 alterations are implicated in multiple cancers, with significant study in thoracic oncology, with an adverse prognosis, aggressive behaviour, metabolic reprogramming and diminished responses to chemotherapy and immunotherapy and increased PD‐L1 expression. However, the clinicopathological significance of NFE2L2 mutations in urothelial carcinoma is not well understood. Methods and results: To address this, we identified six urothelial carcinomas harbouring NFE2L2 mutations from a cohort of 156 muscle‐invasive cases that underwent next‐generation sequencing (NGS). Histological review of the five in‐house cases showed concomitant squamous and myxoid features. Immunohistochemical analysis revealed high PD‐L1 expression, with three of the five cases showing strong, membranous staining in >90% of tumour cells. NGS showed frequent mutations in other genes in addition to the NFE2L2 mutation, most commonly in CDKN2A and TERT promoter. Clinically, all patients presented with or developed metastatic disease and all patients who were not lost to follow up died from the disease (median overall survival: 12 months). Conclusions: These findings suggest that NFE2L2 ‐mutated urothelial carcinomas frequently have concomitant squamous and myxoid features, aggressive behaviour and high PD‐L1 expression. Recognition of the NFE2L2 ‐mutated urothelial carcinomas may have diagnostic and prognostic utility, particularly with immunotherapy and possible targeted therapy against the NRF2 signalling pathway. Further investigation with larger cohorts is warranted to expand the data surrounding NFE2L2 mutations in urothelial carcinoma.
- 6 June 2026
- Published by Wiley in Histopathology
Open AccessNFE2L2 ‐mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD ‐ L1 expression
Aims: NFE2L2 encodes the transcription factor, NRF2, which is a regulator of cellular oxidative stress responses and metabolic homeostasis. NFE2L2 alterations are implicated in multiple cancers, with significant study in thoracic oncology, with an adverse prognosis, aggressive behaviour, metabolic reprogramming and diminished responses to chemotherapy and immunotherapy and increased PD‐L1 expression. However, the clinicopathological significance of NFE2L2 mutations in urothelial carcinoma is not well understood. Methods and results: To address this, we identified six urothelial carcinomas harbouring NFE2L2 mutations from a cohort of 156 muscle‐invasive cases that underwent next‐generation sequencing (NGS). Histological review of the five in‐house cases showed concomitant squamous and myxoid features. Immunohistochemical analysis revealed high PD‐L1 expression, with three of the five cases showing strong, membranous staining in >90% of tumour cells. NGS showed frequent mutations in other genes in addition to the NFE2L2 mutation, most commonly in CDKN2A and TERT promoter. Clinically, all patients presented with or developed metastatic disease and all patients who were not lost to follow up died from the disease (median overall survival: 12 months). Conclusions: These findings suggest that NFE2L2 ‐mutated urothelial carcinomas frequently have concomitant squamous and myxoid features, aggressive behaviour and high PD‐L1 expression. Recognition of the NFE2L2 ‐mutated urothelial carcinomas may have diagnostic and prognostic utility, particularly with immunotherapy and possible targeted therapy against the NRF2 signalling pathway. Further investigation with larger cohorts is warranted to expand the data surrounding NFE2L2 mutations in urothelial carcinoma.
- Open Access
- 16 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1044-1050
Papillary renal cell carcinoma, formerly known as Type 2: a single institutional study addressing histologic and molecular features
Aims: Papillary renal cell carcinoma (pRCC) accounts for 15%–20% of RCC cases and is the second most common histologic subtype of RCC. In contrast to other common RCC subtypes, there continues to be ongoing debate about how to classify RCCs with papillary architecture and eosinophilic cytoplasm given the heterogeneity of histologic, IHC and molecular findings. Our study set out to characterize the histologic features and molecular alterations in cases that were originally diagnosed as pRCC, Type 2 or high‐grade pRCC in a single institutional study ( n = 63). Methods and results: Histologically, the vast majority of the cases had a papillary pattern ( n = 59). There were three cases that had a mixed solid and papillary pattern and one case that had a sarcomatoid architectural pattern. The cases were composed of large cells with eosinophilic cytoplasm, pseudostratified or apically oriented nuclei and prominent nucleoli. Molecular analysis of these cases revealed a wide range of genes that were mutated, with the most common ones being SETD2 ( n = 9), PBRM1 ( n = 5), KDM6A ( n = 7), PMS2 ( n = 4), NF2 ( n = 7) and TERT ( n = 7). Our study further identified cases that had molecular mutations in the RTK/RAS pathway ( KRAS and NRAS ), PI3K pathway ( TSC2 ), TP53 pathway ( TP53 and CHEK2 ) and copy number alterations in the cell cycle pathway ( CDKN2A and CCND3 ). Conclusions: These findings highlight the need to molecularly characterize these lesions as there is no specific histologic finding to identify cases that harbour different pathogenic alterations in specific genes.
- 16 December 2025
- Published by Wiley in Histopathology
- Vol. 88 (5) , 1044-1050
Open AccessPapillary renal cell carcinoma, formerly known as Type 2: a single institutional study addressing histologic and molecular features
Aims: Papillary renal cell carcinoma (pRCC) accounts for 15%–20% of RCC cases and is the second most common histologic subtype of RCC. In contrast to other common RCC subtypes, there continues to be ongoing debate about how to classify RCCs with papillary architecture and eosinophilic cytoplasm given the heterogeneity of histologic, IHC and molecular findings. Our study set out to characterize the histologic features and molecular alterations in cases that were originally diagnosed as pRCC, Type 2 or high‐grade pRCC in a single institutional study ( n = 63). Methods and results: Histologically, the vast majority of the cases had a papillary pattern ( n = 59). There were three cases that had a mixed solid and papillary pattern and one case that had a sarcomatoid architectural pattern. The cases were composed of large cells with eosinophilic cytoplasm, pseudostratified or apically oriented nuclei and prominent nucleoli. Molecular analysis of these cases revealed a wide range of genes that were mutated, with the most common ones being SETD2 ( n = 9), PBRM1 ( n = 5), KDM6A ( n = 7), PMS2 ( n = 4), NF2 ( n = 7) and TERT ( n = 7). Our study further identified cases that had molecular mutations in the RTK/RAS pathway ( KRAS and NRAS ), PI3K pathway ( TSC2 ), TP53 pathway ( TP53 and CHEK2 ) and copy number alterations in the cell cycle pathway ( CDKN2A and CCND3 ). Conclusions: These findings highlight the need to molecularly characterize these lesions as there is no specific histologic finding to identify cases that harbour different pathogenic alterations in specific genes.
- Open Access
Genomics of Acute Myeloid Leukemia at Diagnosis and Remission
Accurate and comprehensive genetic characterization of acute myeloid leukemia (AML) is essential for diagnosis, prognostication, and treatment selection. We report here, in 255 adults with AML enrolled in a prospective clinical protocol at 18 major cancer centers across the USA, the results of whole genome DNA-sequencing (WGS) at diagnosis and post-treatment remission. WGS effectively recapitulated, and frequently identified genetic alterations missed by, conventional standard of care clinical testing. These new findings included important prognostic and predictive biomarkers, copy number alterations, regulatory element, splicing, and structural variants including partial tandem duplications within KMT2A. All patients had a pathogenic variant detected at diagnosis, and approximately ten percent also had evidence of a potential inherited myeloid malignancy predisposition. This comprehensive atlas of adult AML genomics provides novel insights into disease biology, creates an evidentiary basis to support clinical testing improvements, and is a resource for both diagnostics and drug development. . Statement of Significance: Acute myeloid leukemia is a diagnostic category encompassing multiple rare hematological malignances. We show, in this nationwide multicenter study, that standardized unbiased whole genome DNA-sequencing and disease-optimized bioinformatics can replicate conventional “standard of care” AML clinical testing results, while also revealing currently underdiagnosed AML disease biology and potential genetic predisposition.
Open AccessGenomics of Acute Myeloid Leukemia at Diagnosis and Remission
Accurate and comprehensive genetic characterization of acute myeloid leukemia (AML) is essential for diagnosis, prognostication, and treatment selection. We report here, in 255 adults with AML enrolled in a prospective clinical protocol at 18 major cancer centers across the USA, the results of whole genome DNA-sequencing (WGS) at diagnosis and post-treatment remission. WGS effectively recapitulated, and frequently identified genetic alterations missed by, conventional standard of care clinical testing. These new findings included important prognostic and predictive biomarkers, copy number alterations, regulatory element, splicing, and structural variants including partial tandem duplications within KMT2A. All patients had a pathogenic variant detected at diagnosis, and approximately ten percent also had evidence of a potential inherited myeloid malignancy predisposition. This comprehensive atlas of adult AML genomics provides novel insights into disease biology, creates an evidentiary basis to support clinical testing improvements, and is a resource for both diagnostics and drug development. . Statement of Significance: Acute myeloid leukemia is a diagnostic category encompassing multiple rare hematological malignances. We show, in this nationwide multicenter study, that standardized unbiased whole genome DNA-sequencing and disease-optimized bioinformatics can replicate conventional “standard of care” AML clinical testing results, while also revealing currently underdiagnosed AML disease biology and potential genetic predisposition.
- 7 March 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 38 (6) , 100752
Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist
- 7 March 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 38 (6) , 100752
Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist
- 24 July 2023
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 32 (3) , 625-631
Oncocytoma-Like Angiomyolipoma of the Kidney: A Closer Look into the Clinicopathologic, Immunohistochemical, and Molecular Characteristics of a Rare Entity with Review of the Literature
Introduction. Angiomyolipoma (AML) is a mesenchymal neoplasm that belongs to the perivascular epithelioid cell tumor family (PEComa). AMLs can be subtyped into several patterns dependent on cell type, morphology, and tissue composition. One of the patterns, oncocytoma-like AML is a rare entity with only three cases published in the literature. Case presentation. We present a case of a previously healthy 29-year-old woman who underwent a left partial nephrectomy secondary to a 4.6 cm heterogeneous renal neoplasm. Gross examination demonstrated a well-circumscribed renal mass. Modified Giemsa stain preparation showed oncocytic cells in syncytial pattern with ample granular cytoplasm and round nuclei with prominent nucleoli. Histology assessment showed an oncocytic neoplasm with interspersed adipose tissue. The tumor exhibited tubular architecture with the tubules lined by eosinophilic epithelioid cells with nuclear atypia and prominent nucleoli. Thick blood vessels with emanating epithelioid cells were present. High-grade histology features were not identified. The tumor cells were positive for HMB-45 and SMA and negative for PAX8, keratins, KIT, and vimentin. A diagnosis of oncocytoma-like AML was rendered. Next-generation sequencing (NGS) and RNA fusion were performed. NGS revealed no pathogenic variants and RNA fusion identified no rearrangements. Chromosomal copy number alterations were present in the long arm of chromosome 1 (1p) and chromosome 22. Conclusions. We describe and discuss the clinical, cytomorphologic, histologic, and molecular findings of oncocytoma-like AML, a rare renal neoplasm, and provide a review of the literature.
- 24 July 2023
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 32 (3) , 625-631
Oncocytoma-Like Angiomyolipoma of the Kidney: A Closer Look into the Clinicopathologic, Immunohistochemical, and Molecular Characteristics of a Rare Entity with Review of the Literature
Introduction. Angiomyolipoma (AML) is a mesenchymal neoplasm that belongs to the perivascular epithelioid cell tumor family (PEComa). AMLs can be subtyped into several patterns dependent on cell type, morphology, and tissue composition. One of the patterns, oncocytoma-like AML is a rare entity with only three cases published in the literature. Case presentation. We present a case of a previously healthy 29-year-old woman who underwent a left partial nephrectomy secondary to a 4.6 cm heterogeneous renal neoplasm. Gross examination demonstrated a well-circumscribed renal mass. Modified Giemsa stain preparation showed oncocytic cells in syncytial pattern with ample granular cytoplasm and round nuclei with prominent nucleoli. Histology assessment showed an oncocytic neoplasm with interspersed adipose tissue. The tumor exhibited tubular architecture with the tubules lined by eosinophilic epithelioid cells with nuclear atypia and prominent nucleoli. Thick blood vessels with emanating epithelioid cells were present. High-grade histology features were not identified. The tumor cells were positive for HMB-45 and SMA and negative for PAX8, keratins, KIT, and vimentin. A diagnosis of oncocytoma-like AML was rendered. Next-generation sequencing (NGS) and RNA fusion were performed. NGS revealed no pathogenic variants and RNA fusion identified no rearrangements. Chromosomal copy number alterations were present in the long arm of chromosome 1 (1p) and chromosome 22. Conclusions. We describe and discuss the clinical, cytomorphologic, histologic, and molecular findings of oncocytoma-like AML, a rare renal neoplasm, and provide a review of the literature.
- 3 March 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (5) , 589-598
Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins
Subclonal loss of mismatch repair (MMR) proteins has been described in a small subset of endometrial carcinomas (ECs), but the genomic basis for this phenomenon has received limited attention. Herein, we retrospectively evaluated all ECs with MMR immunohistochemistry (n=285) for subclonal loss, and in those (n=6), performed a detailed clinicopathologic and genomic comparison of the MMR-deficient and MMR-proficient components. Three tumors were FIGO stage IA, and one each stage IB, II, and IIIC2. Patterns of subclonal loss were as follows: (1) 3 FIGO grade 1 endometrioid carcinomas with subclonal MLH1/PMS2, MLH1 promoter hypermethylation, and no MMR gene mutations; (2) POLE-mutated FIGO grade 3 endometrioid carcinoma with subclonal PMS2, and PMS2 and MSH6 mutations limited to the MMR-deficient component; (3) dedifferentiated carcinoma with subclonal MSH2/MSH6, as well as complete loss of MLH1/PMS2, MLH1 promoter hypermethylation, and PMS2 and MSH6 mutations in both components; (4) dedifferentiated carcinoma with subclonal MSH6, and somatic and germline MSH6 mutations in both components, but with a higher allele frequency in MMR-deficient foci. Recurrences occurred in 2 patients, one consisted of the MMR-proficient component from a FIGO 1 endometrioid carcinoma, while the other was from the MSH6-mutated dedifferentiated endometrioid carcinoma. At the last follow-up (median: 44 mo), 4 patients were alive and disease-free and 2 were alive with disease. In summary, subclonal MMR loss reflects subclonal and often complex genomic and epigenetic alterations, which may have therapeutic implications and therefore must be reported when present. In addition, subclonal loss can occur in both POLE-mutated and Lynch syndrome–associated ECs.
- 3 March 2023
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 47 (5) , 589-598
Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins
Subclonal loss of mismatch repair (MMR) proteins has been described in a small subset of endometrial carcinomas (ECs), but the genomic basis for this phenomenon has received limited attention. Herein, we retrospectively evaluated all ECs with MMR immunohistochemistry (n=285) for subclonal loss, and in those (n=6), performed a detailed clinicopathologic and genomic comparison of the MMR-deficient and MMR-proficient components. Three tumors were FIGO stage IA, and one each stage IB, II, and IIIC2. Patterns of subclonal loss were as follows: (1) 3 FIGO grade 1 endometrioid carcinomas with subclonal MLH1/PMS2, MLH1 promoter hypermethylation, and no MMR gene mutations; (2) POLE-mutated FIGO grade 3 endometrioid carcinoma with subclonal PMS2, and PMS2 and MSH6 mutations limited to the MMR-deficient component; (3) dedifferentiated carcinoma with subclonal MSH2/MSH6, as well as complete loss of MLH1/PMS2, MLH1 promoter hypermethylation, and PMS2 and MSH6 mutations in both components; (4) dedifferentiated carcinoma with subclonal MSH6, and somatic and germline MSH6 mutations in both components, but with a higher allele frequency in MMR-deficient foci. Recurrences occurred in 2 patients, one consisted of the MMR-proficient component from a FIGO 1 endometrioid carcinoma, while the other was from the MSH6-mutated dedifferentiated endometrioid carcinoma. At the last follow-up (median: 44 mo), 4 patients were alive and disease-free and 2 were alive with disease. In summary, subclonal MMR loss reflects subclonal and often complex genomic and epigenetic alterations, which may have therapeutic implications and therefore must be reported when present. In addition, subclonal loss can occur in both POLE-mutated and Lynch syndrome–associated ECs.
- 30 December 2022
- Published by Elsevier in Human Pathology
- Vol. 134, 124-133
TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases
- 30 December 2022
- Published by Elsevier in Human Pathology
- Vol. 134, 124-133
TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases